Tangen was founded in 2013 and is located in Branford, Connecticut. The Company has developed an innovative platform that enables molecular diagnostic technology to move out of traditional laboratories by providing low cost, portable, and rapid diagnostic capabilities for a variety of applications. There is currently an unmet need in the market for truly flexible nucleic acid-based diagnostic devices, which Tangen’s platform, the Tangen Molecular Diagnostic System (TangenDx™), is designed to fill. What sets TangenDx™ apart from competitors is the capability to detect a broad array of targets simultaneously on a single sample, while maintaining low cost, easy workflow, and extreme sensitivity. Tangen believes that this is the future of diagnostics, and a technology such as the TangenDx™ will eventually bring high quality molecular testing to the traditional laboratory setting, and also to settings outside the laboratory, such as clinics, doctor’s offices, pharmacies, and even into the hands of rural health care providers in less developed regions of the world.

Research Activities:

Tangen Biosciences is continuing to improve the features and capabilities of the TangenDx platform technology. New assay development is as simple as designing customized solutions for sample type and species. Tangen currently has a USG contract to utilize the TangenDx in the design and manufacture of a highly sensitive blood test to diagnose infections occurring in a bioterrorism event involving Anthrax exposure. Future assays will include highly sensitive tests to identify antibiotic sensitivity directly from a patient blood sample, in less than an hour, with no need for accessory equipment, reagent refrigeration, and with minimal training.

Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory. Consilium’s highly-skilled team provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision makers and executives on critical communications programs and stakeholder challenges. The Company has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects.

Consilium represents innovators in the healthcare and biotechnology fields whose science is changing the future of treatments. Consilium Strategic Communications US Inc. offering includes precise executive, corporate, product and financial communications strategies and media relations, reputation building, patient advocacy, health education, social media strategy engagement and activation and crisis communications to deliver sustained results that inspire action and build value.

Real Estate Investment/Property Management & Development Co.

Biohaven is a clinical-stage biopharmaceutical company with proven leadership from industry and academic settings…a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders…and strong support from top-tier biopharma investors.

We’re using a flat and highly entrepreneurial organizational structure – and deep experience in drug development – to leverage a range of intellectual property licensed from companies and institutions that include Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital.

Since our establishment in 2013, and especially since our initial public offering in 2017, we have made rapid progress with multiple compounds across our CGRP receptor antagonist and glutamate modulator platforms. Today, we are ready to achieve a number of new clinical and regulatory milestones , including an NDA filing for rimegepant — our novel, orally-dosed migraine treatment –in 2019, and an NDA filing for BHV-0223, our novel, sublingual formulation of riluzole for patients with ALS in the second half of 2018.

LDiagnostics, a company in New Haven, CT, formed in partnership with Yale University, is devoted to discovery of new diagnostics and therapeutic targets for immunological and infectious diseases.

Research Activities
Discovery of new diagnostics and therapeutic targets for immunological and infectious diseases.

Locke Lord is a full-service, international law firm of more than 20 offices designed to meet clients’ needs around the world. The Firm has a history that spans more than 125 years and is a worldwide leader in the middle market sector. Locke Lord advises clients across a broad spectrum of industries including energy, financial services, fund formation, health care, insurance and reinsurance, private equity and venture capital, real estate, and technology, media and telecommunications, while providing a wealth of experience through its complex litigation, intellectual property, regulatory and transactional teams.

Specialization
Locke Lord’s IP Pharmaceutical and Biotechnology practice pulls together lawyers from across the firm’s many practice areas and offices who are best suited to meet the legal challenges of pharmaceutical and biotechnology industry clients. Our formidable team combines strong scientific understanding, courtroom experience, regulatory experience and industry knowledge. Our lawyers have been recognized in Chambers, Benchmark Litigation’s 2010 Definitive Guide to America’s Leading Litigation Firms and Attorneys, The Best Lawyers in America, and Super Lawyers and our accomplishments have been reported in The American Lawyer, The National Law Journal, and Legal Times. Some of the largest pharmaceutical, biotechnology, and agricultural companies in the world rely on Locke Lord.

At Dilworth IP, we listen to our clients well to better understand their businesses, technologies, people, and vision for success. We appreciate how these factors interrelate. By paying close attention, we can provide the legal counseling, worldwide portfolio management, transactional and agreement support, patent and trademark prosecution, and litigation services our clients need to protect their businesses.

Our clients have broad interests. They manufacture products that make our daily lives better, and their businesses span the biotechnology, pharmaceutical, chemical, polymers, material science, renewable energy, agricultural, and other industries. Dilworth IP’s attorneys have strong academic credentials; several have advanced technical degrees. Most of us worked in industry as research scientists or engineers before studying law. Some have co-authored scientific papers and been inventors on multiple patents. With an average of 20+ years of experience practicing IP law, often as in-house counsel at world-class chemical companies, Dilworth IP’s practitioners understand technology and the importance of protecting it well.

Dilworth IP is lean and flexible. We leverage technology to thrive in the fast-paced global marketplace and deliver world-class legal services to our clients while keeping costs low. We offer competitive rates and alternative fee arrangements without sacrificing performance. Our offices are strategically located in the New York and Washington, D.C. metropolitan areas and in Atlanta, Georgia.

CohnReznick LLP is one of the top advisory, assurance and tax firms in the United States, combining the deep resources of a national firm with the hands-on, agile approach that today’s dynamic business environment demands. With diverse industry expertise, the Firm provides companies with the insight and experience to help them break through and seize growth opportunities. The Firm, with origins dating back to 1919, is headquartered in New York, NY with 2,700 employees in offices nationwide. CohnReznick is a member of Nexia International, a global network of independent accountancy, tax, and business advisors.

For a life sciences company, ongoing innovation, access to capital, and the ability to obtain regulatory approval are the cornerstones for success. Improving operational, financial, and risk management practices as you grow enhances your ability to attract investors, commercialize, and exit when the time is right. CohnReznick’s Life Sciences Industry specialists serve as trusted accounting, tax, and business advisors to assist you in making critical go-forward decisions.

The Department of Economic and Community Development is the state’s lead agency responsible for strengthening Connecticut’s competitive position in the rapidly changing, knowledge-based global economy.

The agency takes a comprehensive approach to economic development that incorporates community development, transportation, education, and arts and culture. Specifically, the department:

  • Supports existing businesses and attracts new businesses and jobs with a wide range of programs and services to help companies prosper;
  • Promotes Connecticut industries and businesses here at home, throughout the country and across the globe;
  • Strengthens Connecticut’s communities by providing funding and technical support for local community and economic development projects;
  • Works to make tourism a leading economic contributor and a source of pride for Connecticut;
  • Develops and strengthens the arts in Connecticut and makes artistic experiences widely available to residents and visitors; and
  • Helps to eliminate brownfield properties by promoting smart growth principles, strengthening public/private partnerships and providing a one-stop resource for expertise.

By coupling UConn’s world-class research resources, facilities, and business support services to a network of experienced investors and entrepreneurs, we help launch startups ready to transform their respective markets.